Cristin-resultat-ID: 1856054
Sist endret: 31. januar 2021, 18:58
NVI-rapporteringsår: 2020
Resultat
Vitenskapelig oversiktsartikkel/review
2020

Epigenetics in breast cancer therapy—New strategies and future nanomedicine perspectives

Bidragsytere:
  • Verona Buociková
  • Ivan Rios Mondragon
  • Eleftherios Pilalis
  • Aristotelis Chatziioannou
  • Svetlana Miklíková
  • Michal Mego
  • mfl.

Tidsskrift

Cancers
ISSN 2072-6694
e-ISSN 2072-6694
NVI-nivå 1

Om resultatet

Vitenskapelig oversiktsartikkel/review
Publiseringsår: 2020
Publisert online: 2020
Volum: 12
Hefte: 12
Artikkelnummer: 3622
Open Access

Importkilder

Scopus-ID: 2-s2.0-85097244666

Beskrivelse Beskrivelse

Tittel

Epigenetics in breast cancer therapy—New strategies and future nanomedicine perspectives

Sammendrag

Epigenetic dysregulation has been recognized as a critical factor contributing to the development of resistance against standard chemotherapy and to breast cancer progression via epithelial-to-mesenchymal transition. Although the efficacy of the first-generation epigenetic drugs (epi-drugs) in solid tumor management has been disappointing, there is an increasing body of evidence showing that epigenome modulation, in synergy with other therapeutic approaches, could play an important role in cancer treatment, reversing acquired therapy resistance. However, the epigenetic therapy of solid malignancies is not straightforward. The emergence of nanotechnologies applied to medicine has brought new opportunities to advance the targeted delivery of epi-drugs while improving their stability and solubility, and minimizing off-target effects. Furthermore, the omics technologies, as powerful molecular epidemiology screening tools, enable new diagnostic and prognostic epigenetic biomarker identification, allowing for patient stratification and tailored management. In combination with new-generation epi-drugs, nanomedicine can help to overcome low therapeutic efficacy in treatment-resistant tumors. This review provides an overview of ongoing clinical trials focusing on combination therapies employing epi-drugs for breast cancer treatment and summarizes the latest nano-based targeted delivery approaches for epi-drugs. Moreover, it highlights the current limitations and obstacles associated with applying these experimental strategies in the clinics.

Bidragsytere

Verona Buociková

  • Tilknyttet:
    Forfatter
    ved Slovenská Akadémia Vied

Ivan Rios Mondragon

  • Tilknyttet:
    Forfatter
    ved Institutt for klinisk odontologi ved Universitetet i Bergen

Eleftherios Pilalis

  • Tilknyttet:
    Forfatter
    ved Academy of Athens

Aristotelis Chatziioannou

  • Tilknyttet:
    Forfatter
    ved Academy of Athens

Svetlana Miklíková

  • Tilknyttet:
    Forfatter
    ved Slovenská Akadémia Vied
1 - 5 av 18 | Neste | Siste »